Ioxilan MedChemExpress (MCE)

Product Name	IOXILAN (400 MG)
Synonyms	IOXILAN (400 MG)
CAS	107793-72-6
EINECS
Chemical Formula	C18H24I3N3O8
Molecular Weight	791.11
inchi
Package	10 mM * 1 mL;5 mg;10 mg
Price	Email to quote
Descriptions	Ioxilan Ioxilan MedChemExpress (MCE) HY-109513 107793-72-6 98.34% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US Descriptions Ioxilan Ioxilan MedChemExpress (MCE) HY-109513 107793-72-6 98.34% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. As a low-osmolar nonionic monomer, Ioxilan increases the safety and tolerance of X-ray contrast agents. The development of Ioxilan is based on the introduction of a double methylene as a hydrophobic region and masking it with a hydrophilic hydroxyl group could lower the osmolality without adversely affecting the biological tolerance[1]. Rapid intravenous injection of water-soluble X-ray contrast agents (Ioxilan) can be performed with dynamic computed tomography to improve the detectability of liver lesions. When injected intravenously, water-soluble, intravenous X-ray contrast agents are largely distributed in the extracellular fluid space and excreted unchanged by the kidneys. Contrast enhancement of a region of interest depends on the route of administration, delivery of the agent to the area by blood flow, and the final iodine concentration in the region[1]. \| \| \| \| \| \| \| \| \| \| [1]. Cheng KT. Ioxilan carbonate particles. National Center for Biotechnology Information (US) 2004-2013. 2007 Sep 1. [Content Brief] [2]. Chow SL, et al. Effect of iodixanol and ioxilan on QT interval and renal function in patients with systolic heart failure. Int J Cardiol. 2012 Jan 12 154(1):17-21. [Content Brief] [3]. Nonionic Contrast Agents.
Supplier Website	https://www.medchemexpress.com/ioxilan.html
Last Update	2025-05-21 16:50:25

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-05-21 16:50:25

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-05-21 16:50:25

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-05-21 16:50:25

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-05-21 16:50:25

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-05-21 16:50:25

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-05-21 16:50:25

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-05-21 16:50:25

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-05-21 16:50:25


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact